ClinicalTrials.gg
CompletedNCT06657105Updated Feb 7, 2025

A Study to Investigate the Pharmacokinetics of Ethinyl Estradiol and Levonorgestrel When Given Alone and in Combination With Baxdrostat in Healthy Females of Non-childbearing Potential

A Phase 1 interventional study of EE/LNG and Baxdrostat in Healthy Participants, sponsored by AstraZeneca. Completed at 1 site in United States. Open to female participants aged 35 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-02-07.

Sponsored by AstraZeneca · Phase 1, Interventional, and Other

From the registry’s dates

  • Primary completion was Feb 2025, 1 year 9 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
22
Allocation
Non-randomized
Ages
35 Years to 75 Years
Sex
Female
01

Study summary

The main purpose of the study is to assess the effect of multiple doses of baxdrostat on the pharmacokinetics (PK) of a single dose of combined oral ethinyl estradiol (EE) and levonorgestrel (LNG). Safety and tolerability of baxdrostat will be assessed during the study.

Read the detailed description

This is an open-label, 3-period fixed sequence study conducted at a single Clinical Unit.

The study will comprise of:

  • A Screening period of maximum 28 days.
  • Period 1: - From Day -1 to Day 5.
  • Period 2: -From Day 6 to Day 16
  • Period 3: - From Day 17 to Day 23.
  • A Final Follow-up Visit, 7 (± 2) days after the last PK sample in Period 3.
02

Conditions studied

  • Healthy Participants

Keywords

  • Baxdrostat
  • Aldosterone
  • Ethinyl estradiol/ Levonorgestrel
03

In context

Lead sponsor

AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.

Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
35 Years to 75 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Females must have a negative pregnancy test at the Screening Visit and Study Day -1 (admission to Clinical Unit) and must not be lactating and must be of non-, confirmed at Screening by fulfilling one of the following criteria:

    1. defined as amenorrhea for at least 12 months following cessation of all exogenous hormonal treatments and FSH levels in the postmenopausal range (Follicular Stimulating Hormone (FSH) > 40 mIU/mL).
    2. Documentation of irreversible surgical sterilization by hysterectomy, bilateral oophorectomy, or bilateral salpingectomy but not tubal ligation or tubal occlusion.
  • Have a (BMI) between 18 and 30 kg/m2

Exclusion criteria

Exclusion Criteria:

  • History of any disease or disorder which, in the opinion of the Investigator
  • History or presence of gastrointestinal, hepatic, or renal disease or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs.
  • Sex hormone therapy within one month before study.
  • History of drug-related hepatic toxicity.
  • History or family history of potential risk of arterial and venous thromboembolic events (eg, factor V Leiden mutation).
  • History of cardiovascular risk (eg, history of myocardial infarction).
  • Any laboratory values with the following deviations at the Screening Visit and Study Day -1 (admission to Clinical Unit).
  • Any positive result on screening for serum , HBcAb, or .
  • History of any treatment with drugs.
  • Current smokers or know history of alcohol or drug abuse.
  • History or ongoing severe allergy/.
  • An increased risk for developing SAEs or a associated with administration of EE, or LNG such as history of thrombosis or thromboembolism, presence of estrogen dependent tumors, hypertension, migraines, and liver disease.
  • Participants treated with strong inhibitors or inducers within 3 months or longer (5 half-lives) prior to first administration of IMP in this study.
  • Plasma donation within one month of the Screening Visit or any blood donation/blood loss > 500 mL during the 3 months prior to the Screening Visit.
  • Has received another new chemical entity (defined as a compound which has not been approved for marketing) within 30 days or 5 half-lives (whichever is longest) of the first administration of IMP in this study.
  • Participants who are vegans or have medical dietary restrictions and vulnerable participants.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
22 participants (actual)

Study arms

  • Experimental
    Period 1: Ethinyl estradiol/Levonorgestrel (EE/LNG)

    Participants will receive oral dose of EE/LNG in the fasted state on Day ,1 followed by PK sampling of EE/LNG for 120 hours (EE 72 hours and LNG 120 hours).

    Drug: EE/LNG

  • Experimental
    Period 2: Baxdrostat

    Participants will self-administer the baxdrostat tablet once a day from Day 6 to Day 16.

    Drug: Baxdrostat

  • Experimental
    Period 3: Baxdrostat + EE/LNG

    Participants will receive baxdrostat once daily on Day 17 to Day 22 and will receive EE+LNG in the fasted state on Day 18, followed by oral dose of EE/LNG PK sampling for 120 hours (EE=72 hours and LNG=120 hours).

    Drug: EE/LNG · Drug: Baxdrostat

Interventions

  • DrugEE/LNG

    EE/LNG tablet will be administered orally.

  • Baxdrostat tablet will be administered orally.

06

What researchers measure

Primary outcomes

  1. Area under concentration-time curve from time zero to infinity (AUCinf)

    To assess the effect of multiple doses of baxdrostat on the PK of a single dose of combined oral EE/LNG in healthy females of non-childbearing potential.

    Time frame: EE: Up to Day 21, LNG: Up to Day 23

  2. Area under concentration-curve from time 0 to the last quantifiable concentration (AUClast)

    To assess the effect of multiple doses of baxdrostat on the PK of a single dose of combined oral EE/LNG in healthy females of non-childbearing potential.

    Time frame: EE: Up to Day 21, LNG: Up to Day 23

  3. Maximum observed drug concentration (Cmax)

    To assess the effect of multiple doses of baxdrostat on the PK of a single dose of combined oral EE/LNG in healthy females of non-childbearing potential.

    Time frame: EE: Up to Day 21, LNG: Up to Day 23

Secondary outcomes

  1. Maximum observed drug concentration (Cmax) of EE/LNG

    To describe the PK of a single dose of combined oral EE and LNG in healthy females of non-childbearing potential.

    Time frame: EE: Up to Day 21, LNG: Up to Day 23

  2. Area under concentration-curve from time 0 to the last quantifiable concentration (AUClast) of EE/LNG

    To describe the PK of a single dose of combined oral EE and LNG in healthy females of non-childbearing potential.

    Time frame: EE: Up to Day 21, LNG: Up to Day 23

  3. Area under concentration-time curve from time zero to infinity (AUCinf) of EE/LNG

    To describe the PK of a single dose of combined oral EE and LNG in healthy females of non-childbearing potential.

    Time frame: EE: Up to Day 21, LNG: Up to Day 23

  4. Time to reach maximum observed concentration (tmax)

    To describe the PK of a single dose of combined oral EE and LNG in healthy females of non-childbearing potential.

    Time frame: EE: Up to Day 21, LNG: Up to Day 23

  5. Terminal elimination half-life (t1/2λz)

    To describe the PK of a single dose of combined oral EE and LNG in healthy females of non-childbearing potential.

    Time frame: EE: Up to Day 21, LNG: Up to Day 23

  6. Terminal rate constant (λz)

    To describe the PK of a single dose of combined oral EE and LNG in healthy females of non-childbearing potential.

    Time frame: EE: Up to Day 21, LNG: Up to Day 23

  7. Ratio of EE or LNG to EE (alone) or LNG (alone) based on AUCinf (RAUCinf)

    To describe the PK of a single dose of combined oral EE and LNG in healthy females of non-childbearing potential.

    Time frame: EE: Up to Day 21, LNG: Up to Day 23

  8. Ratio of EE or LNG to EE (alone) or LNG (alone) based on AUClast (RAUClast)

    To describe the PK of a single dose of combined oral EE and LNG in healthy females of non-childbearing potential.

    Time frame: EE: Up to Day 21; LNG: Up to Day 23

  9. Ratio of EE or LN to EE (alone) or LNG (alone) based on Cmax (RCmax)

    To describe the PK of a single dose of combined oral EE and LNG in healthy females of non-childbearing potential.

    Time frame: EE: Up to Day 21; LNG: Up to Day 23

  10. Number of participants with adverse event (AEs)

    To examine the safety and tolerability of baxdrostat alone and in combination with combined oral EE and LNG.

    Time frame: From screening (Day -28 to Day -2) to 8.5 weeks

  11. Maximum observed drug concentration (Cmax) of Baxdrostat

    To assess the PK of baxdrostat in healthy female participants of non-childbearing potential.

    Time frame: Baxdrostat: Day 18 to Day 22

  12. Observed lowest concentration before the next dose is administered (Day 22 pre-dose) (Ctrough)

    To assess the PK of baxdrostat in healthy female participants of non-childbearing potential.

    Time frame: Baxdrostat: Day 18 to Day 22

07

Study locations

1 site
  • Research Site
    Brooklyn, Maryland 21225, United States
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-leveldata from AstraZeneca group of companies sponsored clinical trials via therequest portal Vivli.org. All requests will be evaluated as per the AZ disclosurecommitment:https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure."Yes",indicates that AZ are accepting requests for IPD, but this does not mean allrequests will be approved.

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2024 to primary completion in Feb 2025, 3 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 23, 2024
First posted
Oct 24, 2024
StartActual
Nov 1, 2024
Primary completionActual
Feb 3, 2025
CompletionActual
Feb 3, 2025
Last update
Feb 7, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 7, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06657105
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Oct 24, 2024
Start date
Nov 1, 2024
Primary completion
Feb 3, 2025
Completion
Feb 3, 2025
Last update
Feb 7, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Baxdrostat

Start the discussion